Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019

AIMS: To investigate temporal trends in time to initiation of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide 1 analogues (cardioprotective glucose‐lowering drugs [GLDs]) in patients with a new dual diagnosis of type 2 diabetes (T2DM) and cardiovascular disease (CVD). MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Funck, Kristian L., Knudsen, Jakob S., Hansen, Troels K., Thomsen, Reimar W., Grove, Erik L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839758/
https://www.ncbi.nlm.nih.gov/pubmed/33140907
http://dx.doi.org/10.1111/dom.14245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839758/
https://www.ncbi.nlm.nih.gov/pubmed/33140907
http://dx.doi.org/10.1111/dom.14245

Ejemplares similares